Eli Lilly & CO Form 4 insider transactions

Anat Hakim, EVP, GC & Secretary of ELI LILLY & Co, sold 5,000 shares of common stock on August 7, 2026 for $1,190.00 per share.

Melissa Seymour, EVP, Global Quality of ELI LILLY & Co, reported multiple transactions in common stock on August 1, 2026.

Gabrielle Sulzberger, a Director of ELI LILLY & Co, received 4 shares of common stock on July 20, 2026.

Juan R Luciano, a Director of ELI LILLY & Co, received 14 shares of common stock on July 20, 2026.

J Erik Fyrwald, a Director of ELI LILLY & Co, received 9 shares of common stock on July 20, 2026.

Ralph Alvarez, a Director of ELI LILLY & Co, received 11 shares of common stock on July 20, 2026.

Eli Lilly Director Gabrielle Sulzberger acquired stock units valued at $1,129.35 as part of her compensation.

Juan R. Luciano, a Director at Eli Lilly & Co., acquired stock units valued at $1,129.35 on June 15, 2026, as part of a deferred compensation plan.

Eli Lilly Director J. Erik Fyrwald acquired stock units valued at $1,129.35 as part of a deferred compensation plan.

Eli Lilly Director Ralph Alvarez acquired stock units valued at $1,129.35 as part of a deferred compensation plan.

Eli Lilly & Co. EVP Ilya Yuffa reported the sale of 2,500 shares of common stock for $1,150.77 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Gabrielle Sulzberger, a Director at Eli Lilly & Co., acquired 5.018 stock units on May 18, 2026, as part of her deferred compensation.

Eli Lilly Director Juan R. Luciano acquired stock units valued at approximately $988.09 per share, totaling over $16,000, as part of a deferred compensation plan.

Eli Lilly Director J. Erik Fyrwald acquired 10,036 shares of common stock on May 18, 2026, as part of a deferred compensation plan.

Director Ralph Alvarez acquired 12,566 stock units of Eli Lilly and Company (LLY) on May 18, 2026, as part of a deferred compensation plan.

Lilly Endowment Inc. reported the sale of Eli Lilly & Co. common stock valued at approximately $13.5 million.

Director Gabrielle Sulzberger acquired 5.39 shares of Eli Lilly & Co. stock through a director compensation deferral plan.

Eli Lilly director Juan R. Luciano acquired 17.303 shares of common stock through a routine transaction.

Eli Lilly director J. Erik Fyrwald acquired 10.78 shares of common stock through the company's directors' deferral plan.

Ralph Alvarez, a Director at Eli Lilly & Co., reported a transaction involving the acquisition of 13.498 shares of common stock, valued at $919.90 per share, as part of a deferred compensation plan.

Eli Lilly Director Juan R. Luciano acquired 16.092 shares of common stock, deferring cash compensation into stock units under the company's Directors' Deferral Plan.

Eli Lilly & Co. Director J. Erik Fyrwald acquired 10.026 shares of common stock through a deferred compensation plan.

Eli Lilly & Co. Director Ralph Alvarez acquired and deferred 12.553 shares of common stock as stock units under the company's deferral plan.

Eli Lilly's EVP, Chief People Officer, Eric Dozier, reported a gift of 481 common shares under a pre-arranged 10b5-1 plan.

Eli Lilly & Co. EVP & CIDO Diogo Rau's beneficial ownership adjusted due to correction of over-withheld tax shares.

Eli Lilly's SVP of Finance and CAO, Donald A. Zakrowski, acquired additional common stock and restricted stock units, signaling increased insider ownership.

Eli Lilly & Co. EVP and President, Ilya Yuffa, acquired 4,162.504 shares of common stock at $1,044.67 per share, increasing his beneficial ownership.

Eli Lilly & Co. EVP Jacob Van Naarden reported the acquisition of 4,865.888 shares of common stock and a transfer of 5,302 shares to a spousal lifetime access trust.

Eli Lilly's EVP Daniel Skovronsky acquired over 15,500 shares of common stock at a price of $1,044.67 per share, increasing his direct beneficial ownership.

Eli Lilly's President, Chair, and CEO, David A. Ricks, acquired 38,913.584 shares of common stock in a pre-planned transaction.